The Canadian government has authorized a startup to export psychedelic substances to Australia for medical purposes. Optimi Health Corp. is trusted with the responsibility of exporting pills laced with psilocybin, a compound found in magic mushrooms, and MDMA, as approved by the health department.
The growing demand is not limited to local magic mushrooms Ontario. Other countries are learning from Canada and beginning to investigate and approve the use of serotogenic compounds for medicinal applications.
Purchase psychedelics online in Canada with confidence and unleash your innate potential through trustworthy sources.
[toc]Key Takeaways:
- Optimi Health, a Vancouver-based startup, has been granted an export license for magic mushroom pills to Australia.
- Psychiatrists with licenses in Australia are allowed to use magic mushrooms in the treatment of chronic depression.
- The course of treatment consists of three sessions spread over five to eight weeks, with each session lasting about eight hours.
The Rise of Psilocybin Capsules in Canada
Optimi, a Vancouver-based startup, aims to use its license to expand the pharmaceutical market for psychedelic substances and secure a head-start advantage.
Seven companies have exported psilocybin, MDMA, or both, strictly for clinical trial purposes. An official from Canada’s health department could not confirm whether these exports were for regular patient use and refrained from revealing the companies due to security reasons.
This milestone places Optimi among a unique group of global suppliers, with the current market favoring clinical over recreational use.
What’s in the Pill?
Although the company has not revealed the specific type of mushroom used in the pill, it works with a range of strains including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, test, and extract its psychedelic mushrooms. This quaint town, populated by approximately 3,000 inhabitants, is situated three hours to the east of Vancouver.
Australia’s Relationship with Psychedelic Mushrooms
Around 1 in every 5 Australians aged between 16 and 85 is projected to grapple with a mental illness. Post-traumatic stress disorder (PTSD) is expected to impact 11% of Australians at one point or another in their lives, whereas anxiety disorders are common in 17% of the population.
While there are numerous ways to manage mental disorders, not all are equally effective for everyone. Patients who don’t respond to certain interventions often struggle to find a treatment strategy that works for them, making them more vulnerable.
Understanding the Process
Australia is at the forefront of psilocybin use, allowing licensed psychiatrists to employ this regulated substance in the treatment of PTSD and treatment-resistant depression.
In a groundbreaking move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and psilocybin mushrooms for therapeutic purposes. The TGA asserted that these substances are safe when used in a medically supervised setting for patients with severe mental illnesses.
This shift has had a transformative effect on many mental health professionals and researchers. The administration of these substances will be strictly monitored; it’s not as simple as taking a pill and leaving.
The typical treatment plan consists of three sessions spread over five to eight weeks. Each session lasts approximately eight hours, during which the therapist stays with the patient at all times.
Canada’s Role in Psilocybin Research
Canada has become a significant center for psilocybin research, contributing greatly to our understanding of this compound. Health Canada, along with various institutions, is leading the charge in investigating psilocybin’s therapeutic potential for treating a range of mental health conditions.
Research institutions no longer need to classify these substances as illegal or rely on unauthorized dispensaries or mushroom shops. The government is now granting certain institutions the permission to grow mushrooms for research purposes.
The increased access to substances once deemed detrimental enables researchers to delve deeper into their possible benefits for many individuals.
A Recurring Trend
The pioneering work in the potential use of psychedelics for mental health and substance abuse treatment, including alcoholism, began in the 1950s. English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer led the early research at the Weyburn The Saskatchewan Mental Hospital. Under the leadership of then-premier Tommy Douglas, the hospital saw significant progress due to the medical community’s freedom to explore their theories.
Dr. Osmond and Dr. Hoffer started investigations into LSD, mescaline, and peyote as potential alternatives to harsh procedures like electroshock therapy and lobotomy. The scope of their research expanded in unanticipated ways, with the pair encouraging doctors, nurses, and support staff to experiment with these substances.
Health Research Institutes of Canada
The Canadian Institutes of Health Research, through the Institute of Neurosciences, Mental Health and Addiction, funds three clinical trials to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Principal Investigator | Budget of the Project |
| A randomized controlled trial | Psychological distress in end-of-life patients with advanced cancer | University of Toronto | Sarah Hales | $928,643 |
| Mechanisms supporting psilocybin psychotherapy for alcohol use disorder treatment | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial comparing single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This research funding will enable a broader understanding of controlled substances’ potential benefits. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Canadian Government, has made this funding possible.
Further Psychedelic Research
In Vancouver, psychiatrists have launched a phase III clinical trial using MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder (PTSD). The treatment involves three eight-hour MDMA sessions, spaced a month apart, alongside nine 90-minute sessions without the drug. This trial holds historical significance as it marks the first clinical investigation of an illegal substance.
It’s been over forty years since a psychedelic substance was last studied.
Getting to Know Psilocybin
A psychedelic compound naturally produced by certain types of mushrooms is psilocybin. Once ingested, it metabolises into psilocin. The psilocin activates serotonin 5-HT2a receptors, which are located on the brain’s cortical pyramidal cells, the primary processing sites.
Local authorities are investigating the substance for its potential to aid with depression, anxiety, addiction, and end-of-life distress by promoting introspection and spiritual enlightenment.
What Makes it a Potential Solution for Depression, PTSD, and Other Conditions?
The active ingredient impacts several areas of the brain, making it potentially beneficial for a range of mental health issues. This therapy has treated numerous patients in Canada and Australia, with promising reported results and minimal side effects such as temporary anxiety or increased blood pressure.
Impact on Neurobiology
- Serotonin Receptor Activation: The compound acts as a partial agonist at serotonin receptors, in particular the 5-HT2A subtype, which plays a significant role in managing our emotions and mood.
- Default Mode Network (DMN) Modulation: The substance reduces DMN activity, encouraging introspection, decreasing rigid thought patterns and promoting emotional flexibility.
- Activation of Prefrontal and Limbic Regions: The antidepressant effects of the compound stem from its influence on the prefrontal and limbic brain regions, including the amygdala. Depressed individuals often show decreased responsiveness to emotional stimuli. The compound heightens responses to positive emotional stimuli in the right amygdala, and decreases or normalizes responses to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: The substance promotes feelings of euphoria, interconnectedness, and emotional openness during and after the experience.
- Enhanced Emotional Processing: The psychedelic experience allows individuals to safely face and process deeply ingrained emotions, traumatic memories, or existential concerns in a supportive setting.
- Spiritual and Existential Insights: Research from Johns Hopkins University and Imperial College London suggests that it could foster enduring positive transformations, such as enhanced well-being, increased life satisfaction, and spiritual growth.
What Can You Discover at Your Nearby Magic Mushroom Outlets?
Want to know how this substance could affect your mental health? Check out magic mushroom stores to find a product that suits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Boosts mood, stimulates creative thinking, and enhances productivity and focus |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Improves wellness and boosts overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Encourages clarity, creativity, and concentration. Includes a potent mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy advantages |
Worldwide Acceptance of Psilocybin
Canada is not the sole country supporting the usage of magic mushrooms for mental health disorders. Countries such as Australia are also endorsing these hallucinogens to tackle conditions like depression and PTSD. They are procuring top-quality psychedelic capsules from trusted countries. Under proper supervision, patients can significantly improve their life quality. Funguyz Canada, a magic mushroom provider, offers a variety of products, from pills to LSD edibles.
Frequently Asked Questions
What are the similarities between psilocybin and MDMA?
Psilocybin and MDMA both hold therapeutic value by enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is beneficial in addressing depression and addiction.
In contrast, MDMA promotes empathy and is beneficial in PTSD treatment. It shows promise in improving emotional processing and therapeutic outcomes, even though it’s classified as a controlled substance.
Is this treatment option available to all Australians?
No. In Australia, people first need to undergo an assessment to check if they are eligible to use this substance. This assessment reviews several factors such as pre-existing heart conditions and history of psychosis, among others. This treatment is only offered to patients who have not benefitted from conventional treatment methods for conditions like depression, anxiety, or PTSD.
What effects could Canada’s export of mushrooms have?
Canada is positioning itself to lead the psychedelics market, much like its standing in the cannabis sector. This could encourage more companies to produce top-quality products. As a result, Canada might emerge as a pioneer in the hallucinogen market, strengthening its economy and enabling other countries to access treatments. This could also discourage other nations from obtaining their hallucinogens from illegal dispensaries or suppliers, thus ensuring safety.
Articles You Might Find Interesting:
